These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 36052083)

  • 1. The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.
    Janssens Y; Joye J; Waerlop G; Clement F; Leroux-Roels G; Leroux-Roels I
    Front Immunol; 2022; 13():959379. PubMed ID: 36052083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine approaches conferring cross-protection against influenza viruses.
    Vemula SV; Sayedahmed EE; Sambhara S; Mittal SK
    Expert Rev Vaccines; 2017 Nov; 16(11):1141-1154. PubMed ID: 28925296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.
    Rosu ME; Kok A; Bestebroer TM; de Meulder D; Verveer EP; Pronk MR; Dekker LJM; Luider TM; Richard M; van den Brand JMA; Fouchier RAM; Herfst S
    J Virol; 2022 Mar; 96(6):e0195921. PubMed ID: 35107371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
    Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
    Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza vaccines: T-cell responses deserve more attention.
    Schotsaert M; Saelens X; Leroux-Roels G
    Expert Rev Vaccines; 2012 Aug; 11(8):949-62. PubMed ID: 23002976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza immunology evaluation and correlates of protection: a focus on vaccines.
    Trombetta CM; Montomoli E
    Expert Rev Vaccines; 2016 Aug; 15(8):967-76. PubMed ID: 26954563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards the knowledge-based design of universal influenza epitope ensemble vaccines.
    Sheikh QM; Gatherer D; Reche PA; Flower DR
    Bioinformatics; 2016 Nov; 32(21):3233-3239. PubMed ID: 27402904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-protective immune responses elicited by live attenuated influenza vaccines.
    Jang YH; Seong BL
    Yonsei Med J; 2013 Mar; 54(2):271-82. PubMed ID: 23364956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
    Kim YH; Bang YJ; Park HJ; Li Ko H; Park SI; Hwang KA; Kim H; Nam JH
    Vaccine; 2020 Sep; 38(39):6141-6152. PubMed ID: 32739118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
    Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
    Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemagglutinin-specific CD4
    Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
    Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA; Ribeiro Dos Santos R; Jose Nunes M; Soni J; Li P; Jain VK; Ofori-Anyinam O
    Braz J Infect Dis; 2017; 21(1):63-70. PubMed ID: 27912069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
    Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
    Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
    Front Immunol; 2019; 10():756. PubMed ID: 31105689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.